29
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Avaliação dos efeitos a curto prazo de programas de conscientização e de terapia com pravastatina em indivíduos de alto risco para doença cardiovascular provenientes de consultórios particulares Translated title: The evaluation of short term effects of awareness programs and pravastatin therapy on subjects from private clinics at high risk for cardiovascular disease

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          OBJETIVO: Avaliar a eficácia de programas de conscientização (PC) sobre o controle de fatores de risco (FR) para doença cardiovascular (DCV). MÉTODOS: Pacientes hipercolesterolêmicos de alto risco para DCV foram divididos em 2 grupos durante 16 semanas. O grupo A (n=417, 54,3±10,0 anos, 55% homens) recebeu orientação verbal e escrita sobre controle de FR, e o grupo B (n=180, 54,4±10,9 anos, 45% homens) apenas orientação verbal. Todos os participantes receberam 10mg/dia de pravastatina por 12 semanas. Avaliaram-se o peso, pressão arterial, o colesterol total (CT) e frações, triglicérides, índices I e II de Castelli (CT/HDL-C e LDL-C/HDL-C) e escores de Framingham. RESULTADOS: No basal, A diferiu de B no HDL-C (40,0±11,0 vs 43,0±11,0mg/dl, p=0,013) e no índice I (8,2±3,0 vs 7,6±2,3, p=0,008). Após 16 semanas as variações % foram maiores em A do que B no CT (-28,0 vs -25,0, p<0,05), LDL-C (-29,0 vs -27,6, p<0,05), HDL-C (+13,7 vs. + 10,8, p<0,05) e índice I (-39,0 vs -33,0; p<0,05). A pravastatina potencializou os efeitos da dieta sobre os lípides. CONCLUSÃO: O PC parece ser mais eficaz a curto prazo, em reduzir os FR para DCV do que a orientação apenas verbal.

          Translated abstract

          PURPOSE: To evaluate short-term efficacy of awareness programs (AP) in reducing coronary heart disease risk factors (CHDRF). METHODS: High risk hypercholesterolemic patients were divided in 2 groups during 16 weeks. Group A (n=417, 54.3±10.0 years, 55% males) received verbal and written orientation on CHDRF control, and group B (n=180, 54.4±10.9 years, 45% males) received only verbal orientation. All participants received pravastatin 10mg q.d. for 12 weeks. The evolution of body weight, arterial pressure, lipid profile, Castelli's I and II indexes (TC/HDL and LDL/HDL), and Framingham scores were evaluated. RESULTS: At baseline, A had a lower HDL-C (40.0±11.0 vs 43.0±11.0mg/dl, p=0.013) and a higher index I (8.2±3.0 vs 7.6±2.3, p=0.008) than B. After 16 weeks, A had greater change than B in TC (-28.0 vs -25.0, p<0.05), LDL-C (-29.0 vs -27.6, p<0.05), HDL-C levels (+13.7 vs +10.8, p<0.05) and in the Castelli's Index (-39.0 vs -33.0; p<0.05). In both groups pravastatin use potentialized the effects of diet on the lipid profile. CONCLUSION: The AP seemed to be more effective than verbal orientation alone in CHDRF reduction at short-term.

          Related collections

          Most cited references14

          • Record: found
          • Abstract: not found
          • Article: not found

          Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel.

            This report of an expert panel of the National Cholesterol Education Program provides new guidelines for the treatment of high blood cholesterol in adults 20 years of age and over. Total cholesterol levels are classified as follows: less than 200 mg/dL--"desirable blood cholesterol"; 200 to 239 mg/dL--borderline-high blood cholesterol; greater than or equal to 240 mg/dL--high blood cholesterol. The guidelines detail which patients should go on to have lipoprotein analysis, and which should receive cholesterol-lowering treatment on the basis of their low density lipoprotein (LDL)-cholesterol levels and status with respect to other coronary heart disease risk factors. Dietary therapy is the primary cholesterol-lowering treatment. The report specifies the LDL-cholesterol levels at which dietary therapy should be started and the goals of therapy, and provides detailed guidance on the nature of the recommended dietary changes. If, after six months of intensive dietary therapy, LDL-cholesterol exceeds specified levels, drug treatment should be considered.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Range of serum cholesterol values in the population developing coronary artery disease

                Bookmark

                Author and article information

                Journal
                abc
                Arquivos Brasileiros de Cardiologia
                Arq. Bras. Cardiol.
                Sociedade Brasileira de Cardiologia - SBC (São Paulo, SP, Brazil )
                0066-782X
                1678-4170
                October 1997
                : 69
                : 4
                : 225-230
                Affiliations
                [01] São Paulo SP orgnameUniversidade de São Paulo orgdiv1Faculdade de Medicina orgdiv2Hospital das Clínicas
                Article
                S0066-782X1997001000001 S0066-782X(97)06900401
                10.1590/S0066-782X1997001000001
                5bd8a8ff-1f55-44ee-8a0f-86b9f5a5b4f6

                This work is licensed under a Creative Commons Attribution 4.0 International License.

                History
                : 13 June 1997
                : 06 August 1997
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 13, Pages: 6
                Product

                SciELO Brazil

                Categories
                Artigos Originais

                cardiovascular disease,doença cardiovascular,hipercolesterolemia,fatores de risco,pravastatina,hypercholesterolemia,risk factors,pravastatin

                Comments

                Comment on this article